Common Contracts

FOURTH AMENDED AND RESTATED INCENTIVE COMPENSATION AGREEMENT

Incentive Compensation Agreement • March 29th, 2023 • Immucell Corp /De/ • In vitro & in vivo diagnostic substances

• Contract Type
  Incentive Compensation Agreement
• Filed
  March 29th, 2023
• Company
  Immucell Corp /De/
• Industry
  In vitro & in vivo diagnostic substances

This Fourth Amended and Restated Incentive Compensation Agreement, dated as of March 28, 2023, is by and between ImmuCell Corporation, a Delaware corporation (the “Company”) and Elizabeth L. Williams (the “Executive”), and replaces and supersedes in its entirety the Third Amended and Restated Incentive Compensation Agreement, dated as of November 11, 2022, between the Company and the Executive.

ImmuCell Corporation THIRD AMENDED AND RESTATED INCENTIVE COMPENSATION AGREEMENT

Incentive Compensation Agreement • November 21st, 2022 • Immucell Corp /De/ • In vitro & in vivo diagnostic substances

• Contract Type
  Incentive Compensation Agreement
• Filed
  November 21st, 2022
• Company
  Immucell Corp /De/
• Industry
  In vitro & in vivo diagnostic substances

This Third Amended and Restated Incentive Compensation Agreement, dated as of November 11, 2022, is by and between ImmuCell Corporation, a Delaware corporation (the “Company”) and Elizabeth L. Williams (the “Executive”), and replaces and supersedes in its entirety the Second Amended and Restated Incentive Compensation Agreement, dated as of March 28, 2022, between the Company and the Executive.